Which company developed Ikorituzumab?

Epcoritumab (Epcoritamab) is an innovative antibody drug jointly developed by AbbVie and Genmab, two of the world's leading biopharmaceutical companies. Its research and development background combines Genmab's deep accumulation in bispecific antibody platform technology and AbbVie's global resources and clinical promotion capabilities in the field of tumor immunotherapy. This powerful strategic cooperation has laid a solid foundation for the rapid advancement and clinical transformation of Epcoritab, making it one of the new immunotherapies that have attracted much attention in the field of non-Hodgkin lymphoma treatment in recent years.

The core design of Epcoritamab is based on Genmab's unique DuoBody® platform, which can construct bispecific antibodies so that one end can accurately recognize the CD20 antigen on the surface of tumor cells and the other end can simultaneously activate the CD3 receptor on the surface of T cells. This dual-target mechanism allows T cells to be effectively guided into the tumor microenvironment and trigger a targeted immune cell-mediated cytotoxic response to directly eliminate tumor cells derived from B cells. Compared with traditional monoclonal antibodies or chemotherapy, this mode of action does not rely on cytotoxic drugs, but achieves anti-tumor effects through the body's own immune system, reflecting the current trend of tumor treatment from "killing viruses" to "activating immunity."

In its cooperation withGenmab, AbbVie not only undertook global clinical trial support for Epcoritamab, but was also responsible for its regulatory affairs, market access and commercial promotion in multiple countries. Currently, this drug has received accelerated approval from the US FDA for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) who have relapsed or been refractory after multiple lines of treatment, and is expanding its indications to other B-cell lymphoma types, such as follicular lymphoma (FL) and high-grade B-cell lymphoma (HGBCL).

Reference materials:https://www.drugs.com/epcoritamab.html